193 related articles for article (PubMed ID: 23128321)
1. Prediction of area under the cyclosporine concentration versus time curve in children undergoing hematopoietic stem cell transplantation.
Dupuis LL; Seto W; Teuffel O; Gibson P; Schultz KR; Doyle JD; Gassas A; Egeler RM; Sung L; Schechter T
Biol Blood Marrow Transplant; 2013 Mar; 19(3):418-23. PubMed ID: 23128321
[TBL] [Abstract][Full Text] [Related]
2. Determination of area under the whole blood concentration versus time curve after first intravenous cyclosporine dose in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
Sibbald C; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
Ther Drug Monit; 2008 Aug; 30(4):434-8. PubMed ID: 18641547
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of limited sampling strategies for estimation of cyclosporine area under the concentration-time curve in hematopoietic stem cell transplant patients.
Hadjibabaie M; Vazirian I; Iravani M; Moosavi SA; Alimoghaddam K; Ghavamzadeh A; Rezaee S
Ther Drug Monit; 2011 Dec; 33(6):673-80. PubMed ID: 22011723
[TBL] [Abstract][Full Text] [Related]
4. IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
Dupuis LL; Sibbald C; Schechter T; Ansari M; Gassas A; Théorêt Y; Kassir N; Champagne MA; Doyle J
Biol Blood Marrow Transplant; 2008 May; 14(5):576-82. PubMed ID: 18410900
[TBL] [Abstract][Full Text] [Related]
5. Limited sampling strategy for cyclosporine (Neoral) area under the curve monitoring in pediatric kidney transplant recipients.
Strong DK; Lai A; Primmett D; White CT; Lirenman DS; Carter JE; Hurley RM; Virji M; Ensom MH
Pediatr Transplant; 2005 Oct; 9(5):566-73. PubMed ID: 16176411
[TBL] [Abstract][Full Text] [Related]
6. Limited sampling strategies for estimating intravenous and oral cyclosporine area under the curve in pediatric hematopoietic stem cell transplantation.
Sarem S; Nekka F; Barrière O; Bittencourt H; Duval M; Teira P; Haddad E; Théorêt Y; Lapeyraque AL; Litalien C
Ther Drug Monit; 2015 Apr; 37(2):198-205. PubMed ID: 25162214
[TBL] [Abstract][Full Text] [Related]
7. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
Windreich RM; Goyal RK; Joshi R; Kenkre TS; Howrie D; Venkataramanan R
Biol Blood Marrow Transplant; 2016 Apr; 22(4):682-689. PubMed ID: 26740371
[TBL] [Abstract][Full Text] [Related]
8. Prediction of intravenous cyclosporine area under the concentration-time curve after allogeneic stem cell transplantation.
Duncan N; Arrazi J; Nagra S; Cook M; Thomson AH; Craddock C
Ther Drug Monit; 2010 Jun; 32(3):353-8. PubMed ID: 20224513
[TBL] [Abstract][Full Text] [Related]
9. Limited sampling strategies for predicting area under the concentration-time curve of mycophenolic acid in islet transplant recipients.
Al-Khatib M; Shapiro RJ; Partovi N; Ting LS; Levine M; Ensom MH
Ann Pharmacother; 2010 Jan; 44(1):19-27. PubMed ID: 19996322
[TBL] [Abstract][Full Text] [Related]
10. Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium.
de Winter BC; van Gelder T; Mathot RA; Glander P; Tedesco-Silva H; Hilbrands L; Budde K; van Hest RM
Ther Drug Monit; 2009 Oct; 31(5):585-91. PubMed ID: 19704401
[TBL] [Abstract][Full Text] [Related]
11. A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients.
Wang CH; Ko WJ; Chou NK; Wang SS
Transplant Proc; 2004 Oct; 36(8):2390-2. PubMed ID: 15561259
[TBL] [Abstract][Full Text] [Related]
12. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.
Wall DA; Chan KW; Nieder ML; Hayashi RJ; Yeager AM; Kadota R; Przepiorka D; Mezzi K; Kletzel M;
Pediatr Blood Cancer; 2010 Feb; 54(2):291-8. PubMed ID: 19743300
[TBL] [Abstract][Full Text] [Related]
13. Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients.
Jin M; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
Bone Marrow Transplant; 2008 Oct; 42(7):455-9. PubMed ID: 18622423
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation.
Inoue Y; Saito T; Ogawa K; Nishio Y; Kosugi S; Suzuki Y; Shibuya Y; Kato M; Takahashi M; Miura I
J Clin Pharm Ther; 2011 Aug; 36(4):518-24. PubMed ID: 21105879
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
[TBL] [Abstract][Full Text] [Related]
16. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis.
Punnett A; Sung L; Price V; Das P; Diezi M; Doyle J; Dupuis LL
Ther Drug Monit; 2007 Dec; 29(6):750-7. PubMed ID: 18043472
[TBL] [Abstract][Full Text] [Related]
17. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
[TBL] [Abstract][Full Text] [Related]
19. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
20. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]